


[0005a] In a first aspect, there is provided a salt of a compound of the formula



in which

$R^1$  stands for methyl, ethyl, butyl, or cyclopropylmethyl,

$R^2$  stands for phenyl, whereby phenyl is substituted with a substituent that is selected from the group that consists of trifluoromethoxy and difluoromethoxy, and

$R^3$  stands for hydrogen, methyl, chlorine, methoxy, or trifluoromethyl,

with methanesulfonic acid.

[0005d] In a second aspect, there is provided a method for the production of a salt of the compounds of Formula (I) as disclosed herein, which comprises the reaction of a compound of Formula (I) with methanesulfonic acid.

[0005e] In a third aspect, there is provided a salt as disclosed herein for use in a method for the treatment and/or prevention of diseases, in particular viral infections, preferably infections with human cytomegalovirus (HCMV) or another representative of the group Herpesviridae.

[0005f] In a fourth aspect, there is provided a pharmaceutical agent that contains a salt as disclosed herein in combination with at least one inert, non-toxic, pharmaceutically suitable adjuvant.


**[0005g]** In a fifth aspect, there is provided the use of a salt as disclosed herein for the production of a pharmaceutical agent for the treatment and/or prevention of viral infections, preferably infections with HCMV, or another representative of the group Herpesviridae.

**[0005h]** In a sixth aspect, there is provided a pharmaceutical agent as disclosed herein for use in a method for the treatment and/or prevention of viral infections, preferably infections with HCMV, or another representative of the group Herpesviridae.

**[0005i]** In a seventh aspect, there is provided the use of a pharmaceutical agent as disclosed herein for the production of a medicament for the treatment and/or prevention of viral infections, preferably infections with HCMV, or another representative of the group Herpesviridae.

#### **DETAILED DESCRIPTION**

**[0005a]** In a first aspect, there is provided a salt of a compound of the formula



in which

$R^1$  stands for methyl, ethyl, butyl, or cyclopropylmethyl,

$R^2$  stands for phenyl, whereby phenyl is substituted with a substituent that is selected from the group that consists of trifluoromethoxy and difluoromethoxy, and

$R^3$  stands for hydrogen, methyl, chlorine, methoxy, or trifluoromethyl,

with an organic sulfonic acid or a solvate or hydrate thereof.

**[0005b]** In a second aspect, there is provided a crystalline N-(1-methyl-2-{[4-(5-methylpyridin-2-yl)piperazin-1-yl]-carbonyl}-1*H*-imidazol-4-yl)-N'-[4-trifluoromethoxyphenyl]urea dimesylate, wherein the powder-XRD diffractogram shows characteristic peaks at approximately 6.37, 11.77, 12.56, 17.17, 18.81, 20.34, 21.47, 23.04, and 35.46 degrees 2theta.

**[0005c]** In a third aspect, there is provided a crystalline N-(1-methyl-2-{[4-(5-methylpyridin-2-yl)piperazin-1-yl]-carbonyl}-1*H*-imidazol-4-yl)-N'-[4-trifluoromethoxyphenyl]urea dimesylate, characterized by a powder-XRD diffractogram as essentially depicted in Fig. 1.

[0005d] In a fourth aspect, there is provided a method for the production of a salt of the compounds of Formula (I) as disclosed herein, which comprises the reaction of a compound of Formula (I) or an acid salt of a compound of Formula (I), which is not a salt of an organic sulfonic acid, with an organic sulfonic acid or a source of organic sulfonate ions in a solvent.

[0005e] In a fifth aspect, there is provided a salt as disclosed herein for use in a method for the treatment and/or prevention of diseases, in particular viral infections, preferably infections with HCMV or another representative of the group Herpesviridae.

[0005f] In a sixth aspect, there is provided a pharmaceutical agent that contains a salt as disclosed herein in combination with at least one inert, non-toxic, pharmaceutically suitable adjuvant.

[0005g] In a seventh aspect, there is provided the use of a salt as disclosed herein for the production of a pharmaceutical agent for the treatment and/or prevention of viral infections, preferably infections with HCMV, or another representative of the group Herpesviridae.


[0005h] In an eighth aspect, there is provided a pharmaceutical agent as disclosed herein for use in a method for the treatment and/or prevention of viral infections, preferably infections with HCMV, or another representative of the group Herpesviridae.

[0005i] In a ninth aspect, there is provided the use of a pharmaceutical agent as disclosed herein for the production of a medicament for the treatment and/or prevention of viral infections, preferably infections with HCMV, or another representative of the group Herpesviridae.

## **DETAILED DESCRIPTION**

Claims

1. Salt of a compound of the formula



in which


- $R^1$  stands for methyl, ethyl, butyl, or cyclopropylmethyl,  
 $R^2$  stands for phenyl, whereby phenyl is substituted with a substituent that is selected from the group that consists of trifluoromethoxy and difluoromethoxy, and  
 $R^3$  stands for hydrogen, methyl, chlorine, methoxy, or trifluoromethyl,

with ~~an organic methanesulfonic acid or a solvate or hydrate thereof.~~

~~2. Salt according to Claim 1, characterized in that the organic sulfonic acid is methanesulfonic acid.~~

~~32. Salt according to Claim 21, wherein it is a dimesylate salt.~~

~~43. Salt according to Claim 32 with the following formula:~~



~~54.~~ Salt according to any of Claims 1 to 3, characterized by ~~C~~crystalline N-(1-methyl-2-~~{~~[4-(5-methylpyridin-2-yl)piperazin-1-yl]-carbonyl~~}~~-1*H*-imidazol-4-yl)-N'-[4-trifluoromethoxyphenyl]urea dimesylate, ~~further characterized in that wherein the X-ray powder~~ ~~XRD~~ diffractogram (XRD) shows characteristic peaks at approximately ~~6.37, 11.77, 12.56, 17.17, 18.81, 20.34, 21.47, 23.04, and 35.46 degrees 2-theta when recorded with a Rigaku MiniFlex X-ray powder spectrometer (XRD).~~

65. Salt according to any of Claims 1 to 4, characterized by ~~C~~crystalline N-(1-methyl-2-~~{~~[4-(5-methylpyridin-2-yl)piperazin-1-yl]-carbonyl~~}~~-1*H*-imidazol-4-yl)-N'-[4-trifluoromethoxyphenyl]urea dimesylate, ~~further characterized by an X-ray powder~~ ~~XRD~~ diffractogram (XRD) as essentially depicted in Fig. 1-, ~~when recorded with a Rigaku MiniFlex X-ray powder spectrometer (XRD).~~

7.6. Method for the production of a salt of the compounds of Formula (I) according to Claim 1, which comprises the reaction of a compound of Formula (I) ~~or an acid salt of a compound of Formula (I), which is not a salt of an organic sulfonic acid, with an organic methanesulfonic acid or a source of organic sulfonate ions in a solvent.~~

87. Salt according to one of Claims 1 to ~~6~~5 for use in a method for the treatment and/or prevention of diseases, in particular viral infections, preferably infections with human cytomegalovirus (HCMV) or another representative of the group Herpesviridae.

98. Pharmaceutical agent that contains a salt according to one of Claims 1 to ~~6~~5 in combination with at least one inert, non-toxic, pharmaceutically suitable adjuvant.

~~109.~~ Pharmaceutical agent according to Claim 98, wherein it comprises 5 to 12.5 mg/ml of a salt according to one of Claims 1 to ~~6~~5, 50 to 150 mg/ml of hydroxypropyl- $\beta$ -cyclodextrin, 0.5 to 2.0 mg/ml of sodium acetate as well as water and optionally other pharmaceutically harmless adjuvants.

~~110.~~ Use of a salt according to one of Claims 1 to ~~6~~5 for the production of a pharmaceutical agent for the treatment and/or prevention of viral infections, preferably infections with HCMV, or another representative of the group Herpesviridae.

~~12~~11. Pharmaceutical agent according to Claim ~~9~~8 or ~~10~~9 for use in a method for the treatment and/or prevention of viral infections, preferably infections with HCMV, or another representative of the group Herpesviridae.

~~13~~12. Use of a pharmaceutical agent according to Claim ~~9~~8 or ~~10~~9 for the production of a medicament for the treatment and/or prevention of viral infections, preferably infections with HCMV, or another representative of the group Herpesviridae.